Hepion Pharmaceuticals (HEPA) Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial...

Completion of Enrollment Remains on Track for Q1, 2024 "While we recently had fireworks, we could be looking at real fireworks in the coming year....

Hepion (HEPA) Back in the Spotlight, Gains 230% in May.

Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers. Definitely NOT for traders or...

And We Have a $26.4 Billion Winning Trifecta!

THREE PREVIOUS WINNERS* Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired by Gilead Sciences (GILD) Dicerna (DRNA) $3.30 to $38.25 up...

Revive Therapeutics (RVVTF) Enters the Danger Zone.

What Danger You Ask? Danger #1, the FDA doesn't like the data, and you own the stock. Danger #2, the FDA does like the data, and...

Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...

We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10 Price Targets....

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous...
Biotech Stock Review

Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021 @$1.80Cash has Risen From $3.3 Million...

Hapbee (HAPB) Expands Leadership Team to Support Aggressive Growth Strategy

VANCOUVER, BC, Aug. 6, 2021 /CNW/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee" or the "Company"), the leading wearable, wellness technology company has announced the appointment...

Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE Citius announced that the DMC interim safety and...

Preventing Type I Diabetes. Here’s How Provention (PRVB) Works.

Here's How Provention's Treatment Works. Interview With an Actual Provention Bio (PRVB) Clinical Trial Participant. Conversation Between a Mikayla a Teenager who was at...

Latest article

Cardiol Therapeutics (CRDL) May 2025 Presentation.

Click here to open. RELATED: Cardiol’s (CRDL) Game-Changing Solution for Heart Inflammation? | David Elsley CEO – Video Interview

Nice Bounce on Alkaline Water (WTER) up 81%.

Well now that ain't bad, up 81%! Our outlook on The Alkaline Water Company, our "comeback of the decade" story, is "let's see what...

Zomedica Corp (ZOMDF) $0.05

Company Overview Background Zomedica Corp., incorporated in 2013 under the Business Corporations Act (Alberta), is headquartered in Ann Arbor, Michigan. Initially listed on the TSX Venture...